Skip to content
CancerIndex

Publication

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.

Authors not recorded

J Transl Med2013PMID 24088382PMC3850695stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
24088382
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
PIK3CA E542K + PTEN LossPIK3CAPTEN1
CapivasertibMalignant Gastric NeoplasmPredictiveDSupports Sensitivity Response2submitted
EID11063

In a panel of 20 gastric cancer cell lines, the line that showed greatest sensitivity to AZD5363 in MTS cell proliferation assay contained both PIK3CA E542K and PTEN Loss.

PMID 24088382 · Li et al., 2013 · Open in CIViC

civic
PIK3CA Mutation1
CapivasertibMalignant Gastric NeoplasmPredictiveDSupports Sensitivity Response3accepted
EID1501

In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mo… (full text at CIViC)

PMID 24088382 · Li et al., 2013 · Open in CIViC

civic
PTEN Loss2
Capivasertib + DocetaxelCombinationMalignant Gastric NeoplasmPredictiveDSupports Sensitivity Response1accepted
EID1500

A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the … (full text at CIViC)

PMID 24088382 · Li et al., 2013 · Open in CIViC

civic
DocetaxelMalignant Gastric NeoplasmPredictiveDSupports Resistance2accepted
EID11064

SGC020 was a gastric PDGCX mouse model established from a gastric cancer patient, with a PTEN exon 2-6 gene deletion resulting in undetectable PTEN protein expression. The chemotherapy Taxotere was gi… (full text at CIViC)

PMID 24088382 · Li et al., 2013 · Open in CIViC

civic